Search

Development of a diagnostic instrument to manage hemostasis in chronic liver dise

Company: HemoSonics, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): The clinical evaluation and management of hemostasis in the 5 million patients affected by chronic liver diseases (CLD) is poorly understood. Data presented at two International Symposia on Coagulation in Liver Disease and summarized in a recent edition of… more

Development of a point of care diagnostic to guide efficient usage of blood produ

Company: HemoSonics, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Over 60% of the 600,000 patients undergoing cardio-pulmonary bypass (CPB) procedures in the US each year experience intra- and post-operative bleeding. Treatment options are available, each corresponding to a specific h emostatic defect: (a) fresh frozen plasma… more

Second Generation Companion Mics System

Company: Etymotic Research, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Approximately 10 percent of hearing aid wearers have 10 dB loss of ability to understand speech in noise, in the sense that they require a signal-to-noise ratio 10 dB better than normal-hearing listeners. Since at m any restaurants and social gatherings the… more

The Development of Immune-based Therapies Using Plant Derived Compounds to Attenu

Company: GOLDEN SOY, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Secondary metabolites will be extracted from a specific plant material to identify and isolate immune active components. These components are proposed to enhance the innate and adaptive immune systems by modulating cert ain cytokine levels in white blood cells… more

Not Available

Company: STC BIOLOGICS, INC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: The goal of this project is to develop STC trastuzumab, a generic version of Herceptin. Trastuzumab is a monoclonal antibody made against the HER2 protein that is overexpressed in 20-25% of patients with breast cancer. Because of very high cost associated with prescribing Herceptin, a generic… more

Fitness Games Product Development Platform

Company: HEARTRATE GAMES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): HeartRate Games' objective is to speed the pace of fitness games innovation by giving developers a set of technology tools that make it easier to create great products combining fitness games with the proven benefits of cardio exercise machines. Fitness games… more

Starch-Entrapped Microspheres [Nutrabiotix Fiber] for Gut Health

Company: NUTRABIOTIX, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): To establish the proof of concept that Nutrabiotix fiber is safe and well tolerated, promotes gut health by increasing production of short chain fatty acids and changes colonic microbiota composition in favor of bifidob acteria, improves bowel habit and increase… more

Ototoxicity protection with intratympanic steroid implant

Company: O-RAY PHARMA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Chemotherapy-induced ototoxicity is damage to the inner ear that is caused by the side effects of administered drugs. This can lead to permanent hearing loss and/or tinnitus (continuous ringing in the ear) in the patient. Some of the most common kinds of drugs… more

CIRCULATING TUMOR CELL ENUMERATION PRODUCT

Company: EPIC SCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: 'This project was funded as a Phase I contract by the NCI Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program in response to funding announcement number 272 "Point of Care Analysis of Circulating Tumor Cells for Cancer Diagnostics, Prognosis, and… more

To demonstrate the feasibility of a home tonometer to monitor IOP without contact

Company: ACHEVE TECHNOLOGY, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): This research is to study the feasibility of an in-home tonometer based on the two color strobe technology (TCST) developed by CeeMaxTM Ophthalmic, a division of Achevi Technology. We are the manufacturer of ophthalmic diagnostic instruments with core expertise… more

Human Variation Detection and Visualization on the DNAnexus Web 2.0 platform

Company: DNANEXUS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): DNAnexus proposes to develop a complete solution for the identification and stratification of personal genetic variation from ultra-high-throughput sequencing projects. The solution will be implemented as a Web 2.0 serv ice and online browsing tool that will… more

Feasibility of a Web-based Collaborative Care Support(SM)Model to Improve Care fo

Company: LONGITUDE HEALTH, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Diabetes costs the United States an estimated 174 billion annually. About two-thirds of costs arise from direct medical expenditures, and the remainder accrues from disability, work loss, and premature mortality. Assoc iated cardiovascular comorbidities result… more

Millikan Sequencing by Label-Free Detection of Nucleotide Incorporation

Company: CAERUS MOLECULAR DIAGNOSTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): The feasibility of a label-free technology, Millikan Sequencing, will be evaluated for de novo sequencing of mammalian genomes for under 1,000. This novel sequencing-by-synthesis approach measures the increased charg e as nucleotides are added to DNA templates… more

Gastric Sleeve Magnetic Implant

Company: 3DT HOLDINGS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): The occurrence of obesity is increasingly growing, and it has been projected that 40% of the US population will be obese by the year 2025. The World Health Organization estimates over 1.6 billion adults (age 15+) are ov erweight, and at least 400 million are… more

Multi-Functional Guidewire for Peripheral Vasculature

Company: 3DT HOLDINGS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Over 8 million Americans have peripheral vascular disease (PAD). Percutaneous transluminal artery (PTA) treatment of severe PAD involves the use of balloons and stents, but delivery of these therapies is often suboptimal due to inaccuracies in angiographic… more

Portable device for monitoring water balance in elderly

Company: 3DT HOLDINGS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Transseptal (TS) access for left heart procedures is an important and rapidly growing space for diagnostics and therapy delivery with an expected total of over 10 million U.S. patients. In the U.S. and/or Europe, TS access procedures are used for atrial… more

A mechanism-based computational tool to optimize pulmonary drug delivery

Company: 3DT HOLDINGS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Coronary artery disease (CAD) is a national and worldwide epidemic that places the largest clinical and economic burden on the healthcare system of any disease condition. Patients with stable and acute coronary conditions are often treated with percutaneous… more

Expanding Precision Particle Fabrication Technology for the Widespread Control of

Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): This overall goal of this project is to develop a scalable process for fabricating oil encapsulated particles with uniform sizes and physical characteristics that contain oil as a vehicle for delivering hydrophobic drug s. Poorly water soluble active… more

Multi-day Pain Management Therapy with Novel Injectable Formulation

Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: DESCRIPTION (provided by applicant): Our long term goal is to widespread the use of PPF technology for promoting effective production of drug-encapsulating microparticles with uniform size and physical characteristics that can be leveraged to release a specific drug at controlled rates over… more

Precision Particle Fabrication-enabled Betamethasone-loaded Microspheres for Tran

Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Current approaches to treat sudden sensorineural hearing loss (SSNHL) do not maintain inner ear drug concentrations within an appropriate therapeutic window for sufficient lengths of time to achieve therapeutic effect.A novel delivery system for long-term,… more

Engineering Microparticles for Taste-Masking and Controlled Release of Pediatric

Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Pediatric drug development presents many unique challenges in the effective treatment of diseases in children, from adequate dosing information and pediatric-specific testing to palatable flavor profiles and effective delivery formats. A novel technology that… more

Hemostatic-antibiotic Combination for Prevention of MRSA Surgical Site Infections

Company: CEREMED, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Ostene is a soft, synthetic, moldable hemostatic material that sticks well to cut bone surfaces and stops bleeding by mechanical occlusion. Ostene is a combination of biocompatible water-soluble polymers which are absor bed completely within 24 to 48 hours of… more

Discovery and Development of Novel Glucose Dependent Partial Glucokinase Activato

Company: CALASIA PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Type 2 diabetes (T2DM) is a chronic metabolic disease that affects the quality and longevity of life. Currently it is estimated that about 246 million people worldwide and diabetic and their number is expected to increa se to 380 million by 2025. Further, the… more

Selective and dual-acting Hsp90 and TRAP1 inhibitors

Company: CALASIA PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Although the existing agents for treating cancer have shown promising results, the inherent genetic plasticity of the cancer cells continues to undermine the efficacy of these treatments. One of the possible solutions t o address this problem is to attack the… more

Microfluidic DNA Sequencing

Company: GNUBIO, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Most next-generation DNA sequencing methods have focused on either 1) template amplification followed by massively-parallel sequencing-by-synthesis, or 2) single molecule detection. The first method is now commercially available but suffers from relatively… more